Cardiovascular Risks in Disease: From Muscular Dystrophy to Cancer and COVID-19
DOI:
https://doi.org/10.5281/Keywords:
cardio toxicity, dystrophic protein, COVID-19, dystrophinopathy, anthracyclines, hydroxychloroquine, hypercoagulableAbstract
Cardiovascular complications are prevalent in a range of medical conditions, affecting morbidity and mortality rates globally. This paper explores the intricate relationships between cardiovascular diseases (CVDs) and comorbidities in specific medical conditions, including muscular dystrophy, cancer therapies, and COVID-19. The study outlines the pathophysiological mechanisms that contribute to the development of cardiovascular issues in these diverse diseases, emphasizing shared risk factors, diagnostic challenges, and treatment strategies. Understanding these associations is crucial for improving patient outcomes and developing integrated approaches to manage both primary and secondary disease processes.
References
[1] Р. Панчева and Б. Стоименов, "Кардиомиопатия при пациент с мускулна дистрофия тип Дюшен," Редки болести и лекарства сираци, vol. 12, no. 3, pp. 10-14, 2021.
[2] D. Krasimirova, B. Stoimenov, S. Naydenska, K. Genov, and V. Penchev, "Fracture Risk and Obstructive Sleep Apnoea," Journal of IMAB–Annual Proceeding Scientific Papers, vol. 29, no. 4, pp. 5145-5149, 2023.
[3] B. Stoimenov, L. Gaydarski, S. Dineva, and R. Pancheva, "Case of a female patient with ankylosing spondylitis and multiple aneurysms," Journal of IMAB–Annual Proceeding Scientific Papers, vol. 30, no. 1, pp. 5308-5313, 2024.
[4] N. Valchev and M. Gramatikova, "Risk Factors Associated with In-Hospital Mortality in patient with severe COVID-19 infection," Journal of IMAB–Annual Proceeding Scientific Papers, vol. 30, no. 1, pp. 5369-5374, 2024.
[5] B. Stoimenov and R. Pancheva, "ATRIAL CARDIOMYOPATHY AND STROKE PRE-VENTION-REVIEW," Journal of IMAB, vol. 30, no. 2, p. 2, 2024.
